In the future, we will validate our mechanisms in animal experiments, analyze the therapeutic effect of DDP in LC patients upon RBM15 regulation, investigate whether affecting the activity of RBM15 and KDM5B through drug intervention would impact DDP resistance, verify the regulation of GPX4/ACSL4 by FER1L4/KCNQ1OT1, explore the function of FER1L4 in the ceRNA mechanism and the reasons for the high expression of RBM15 in LC, so as to provide more theoretical knowledge for LC chemotherapy. This evidence concerns the gene ACSL4 and laryngotracheoesophageal cleft.